LY3410738   Click here for help

GtoPdb Ligand ID: 12340

Synonyms: example 2 [US11001596B2] | LY-3410738
Compound class: Synthetic organic
Comment: LY3410738 is a clinical stage orally bioactive, covalent mutant isocitrate dehydrogenase (IDH1) inhibitor [2]. It was developed for potential to treat cancers that are driven by the oncometabolite 2-hydroxyglutarate (2-HG) that is generated by mutated IDH1.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 90.9
Molecular weight 504.28
XLogP 3.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CCN(CC1)[C@H](c1ccc(cc1)[C@@H](Nc1ncc2c(n1)N(CC)C(=O)OC2)C)CC1CC1
Isomeric SMILES CCN1c2nc(ncc2COC1=O)N[C@@H](C)c1ccc(cc1)[C@H](CC1CC1)N1CCN(CC1)C(=O)C=C
InChI InChI=1S/C28H36N6O3/c1-4-25(35)33-14-12-32(13-15-33)24(16-20-6-7-20)22-10-8-21(9-11-22)19(3)30-27-29-17-23-18-37-28(36)34(5-2)26(23)31-27/h4,8-11,17,19-20,24H,1,5-7,12-16,18H2,2-3H3,(H,29,30,31)/t19-,24-/m0/s1
InChI Key AFGYODUJVVOZAX-CYFREDJKSA-N
References
1. Bauer RA, Boulet EL, Burkholder TP, Hahn PJ, Rankovic Z. (2021)
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors.
Patent number: US11001596B2. Assignee: Eli Lilly and Co. Priority date: 08/12/2007. Publication date: 11/05/2021.
2. Cleary JM, Rouaisnel B, Daina A, Raghavan S, Roller LA, Huffman BM, Singh H, Wen PY, Bardeesy N, Zoete V et al.. (2022)
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.
NPJ Precis Oncol, 6 (1): 61. [PMID:36056177]